BACKGROUND: Cotrimoxazole is recommended for prevention of opportunistic infections in symptomatic HIV patients in sub-Saharan Africa. METHODS: We examined the feasibility and effectiveness of daily cotrimoxazole prophylaxis in a well-established cohort of HIV-infected adults attending clinics in Entebbe, Uganda. We compared mortality and morbidity rates for 12 months before and after the introduction of cotrimoxazole. RESULTS: Between August 2000 and February 2002, 94% of cohort members were enrolled onto cotrimoxazole prophylaxis. Revisits were scheduled every 4 weeks to replenish pills; patients attended 61% of revisits. The main reasons for nonenrollment and defaulting were lack of transport, being away from home, and sickness. Drug-related adverse events, mainly itching and rash, were seen in 4% of participants. Although bacterial resistance rate to cotrimoxazole was high, the adjusted mortality incidence rate ratio was significantly reduced after the introduction of cotrimoxazole (0.76; 95% confidence interval, 0.60-0.96; P = 0.020). Overall febrile events and morbidity rates were unchanged after the introduction of cotrimoxazole, but the incidence of malaria was reduced (incidence rate ratio, 0.31; 95% confidence interval, 0.13-0.72). CONCLUSIONS: Cotrimoxazole prophylaxis can be introduced into routine HIV clinic activities and is associated with a reduction in overall mortality and malaria morbidity, even in an area with high bacterial resistance. These results reinforce the need for large-scale provision of cotrimoxazole prophylaxis for all HIV-positive patients in developing countries.
BACKGROUND: Cotrimoxazole is recommended for prevention of opportunistic infections in symptomatic HIV patients in sub-Saharan Africa. METHODS: We examined the feasibility and effectiveness of daily cotrimoxazole prophylaxis in a well-established cohort of HIV-infected adults attending clinics in Entebbe, Uganda. We compared mortality and morbidity rates for 12 months before and after the introduction of cotrimoxazole. RESULTS: Between August 2000 and February 2002, 94% of cohort members were enrolled onto cotrimoxazole prophylaxis. Revisits were scheduled every 4 weeks to replenish pills; patients attended 61% of revisits. The main reasons for nonenrollment and defaulting were lack of transport, being away from home, and sickness. Drug-related adverse events, mainly itching and rash, were seen in 4% of participants. Although bacterial resistance rate to cotrimoxazole was high, the adjusted mortality incidence rate ratio was significantly reduced after the introduction of cotrimoxazole (0.76; 95% confidence interval, 0.60-0.96; P = 0.020). Overall febrile events and morbidity rates were unchanged after the introduction of cotrimoxazole, but the incidence of malaria was reduced (incidence rate ratio, 0.31; 95% confidence interval, 0.13-0.72). CONCLUSIONS: Cotrimoxazole prophylaxis can be introduced into routine HIV clinic activities and is associated with a reduction in overall mortality and malaria morbidity, even in an area with high bacterial resistance. These results reinforce the need for large-scale provision of cotrimoxazole prophylaxis for all HIV-positive patients in developing countries.
Authors: Alphonse Okwera; David K Mafigiri; David Guwatudde; Christopher Whalen; Moses Joloba Journal: Afr Health Sci Date: 2015-03 Impact factor: 0.927
Authors: Ronald K Ottichilo; Christina S Polyak; Bernard Guyah; Benson Singa; Josphat Nyataya; Krista Yuhas; Grace John-Stewart; John N Waitumbi Journal: J Infect Dis Date: 2016-10-25 Impact factor: 5.226
Authors: Anand A Date; Marco Vitoria; Reuben Granich; Mazuwa Banda; Mayada Youssef Fox; Charlie Gilks Journal: Bull World Health Organ Date: 2009-10-23 Impact factor: 9.408
Authors: C O Falade; B Adesina-Adewole; H O Dada-Adegbola; I O Ajayi; J O Akinyemi; O G Ademowo; I F Adewole; P Kanki Journal: Pathog Glob Health Date: 2013-03 Impact factor: 2.894
Authors: Judd L Walson; Elizabeth R Brown; Phelgona A Otieno; Dorothy A Mbori-Ngacha; Grace Wariua; Elizabeth M Obimbo; Rose K Bosire; Carey Farquhar; Dalton Wamalwa; Grace C John-Stewart Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731